title: Co-administration of ramelton and fluvoxamine to increase levels of interleukin-2.
abstract: Ramelton is a medication recently approved by the FDA for treatment of insomnia. Ramelton is an analogue of melatonin with a higher affinity even than that of the natural ligand. Clinically this potentially strong effect of the ligand is blunted by the fact that upon oral ingestion there is first pass metabolism of greater than 95%. This liver metabolism is mediated by the CYP1A2 enzyme. It turns out that the medication fluvoxamine approved by the FDA for the treatment of obsessive compulsive disorder is a potent inhibitor of the CYP1A2 enzyme, with the effect that co-administration of ramelton and fluvoxamine increases blood levels of ramelton by 100-200 fold. It turns out that lymphocytes bear the melatnonin receptors and stimulation of these receptors on lymphocytes cause the lymphocytes to elaborate the pro-inflammatory cytokine interleukin-2 (Il-2). Thus, here we point out that co-administration of ramelton and modest doses of fluvoxamine may be able to smoothly produce increased levels of Il-2, this may be useful in diseases and conditions such as metastatic cancer and maintenance of suppression of the HIV virus.
authors.affiliation: Department of Psychiatry, University of Vermont, 2 Church Street, Burlington, VT 05401, United States. recast@email.com
authors.forename: Richard E
authors.initials: RE
authors.lastname: Kast
authors.forename: Eric Lewin
authors.initials: EL
authors.lastname: Altschuler
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000284:Administration, Oral; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology; D065609:Cytochrome P-450 CYP1A2 Inhibitors; D004338:Drug Combinations; D016666:Fluvoxamine / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis*; D008099:Liver / Q000201:enzymology / Q000378:metabolism; D008214:Lymphocytes / Q000378:metabolism; D008550:Melatonin / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D008954:Models, Biological; D044094:Receptors, Melatonin / Q000187:drug effects / Q000378:metabolism
chemical_list: D000276:Adjuvants, Immunologic; D018687:Antidepressive Agents, Second-Generation; D065609:Cytochrome P-450 CYP1A2 Inhibitors; D004338:Drug Combinations; D007376:Interleukin-2; D044094:Receptors, Melatonin; D008550:Melatonin; D016666:Fluvoxamine